UF Innovate | Sid Martin Biotech client Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), announces the publication of a collaborative study investigating an additional mechanism of action of the company’s lantibiotic compounds, which shows the formation of water permeating pores across bacterial cell membranes. This novel mechanism of action is believed to cause disruption of the bacterial membranes and contribute to the company’s compounds’ antimicrobial mechanism of action. The study was published in the recent issue of Physical Chemistry Chemical Physics and results from its recent collaboration with researchers from Florida International University (FIU).
“Our lantibiotics were previously believed not to form functional pores and only rely on binding to, and abduction of, Lipid II for antimicrobial efficacy. This published study provides further insight into the dual mode of action of compounds in our pipeline, and may contribute to the unique efficacy profile that is observed for these compounds,” stated Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. “There remains a dire need for new approaches to fighting antibiotic-resistant infections, and this study into our lantibiotic program opens up new avenues to create lantibiotics homologs that can address an unmet clinical need.”Learn more about Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action.